ArticleThe Journal of dermatology2020
Questionnaire-based epidemiological study of hidradenitis suppurativa in Japan revealing characteristics different from those in Western countries.
Article in The Journal of dermatology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 26 citations in OpenAlex.
- Long-term analysis of adalimumab in Japanese patients with moderate to severe hidradenitis suppurativa: Open-label phase 3 results.The Journal of dermatology · 2021Trial
- Decreased HDL-C in hidradenitis suppurativa: association with systemic inflammatory phenotype and implications for risk stratification.Lipids in health and disease · 2026Article
- Laboratory Parameters Can Serve as Objective Auxiliary Tools for Assessing Disease Severity in Hidradenitis Suppurativa: A 5-Year Period Single-Center Retrospective Study.Clinical, cosmetic and investigational dermatology · 2026Article
- A link between smoking behaviors and the risk of hidradenitis suppurativa in diabetic patients.PloS one · 2025Article
- The Disease Burdens of Self-diagnosed Hidradenitis Suppurativa Patients in Japan: A Cross-sectional Web-based Survey.Acta dermato-venereologica · 2024Article
- Incidence, Risk Factors, and Prognosis of Hidradenitis Suppurativa Across the Globe: Insights from the Literature.Clinical, cosmetic and investigational dermatology · 2023Review
- Real-world safety and effectiveness of adalimumab in patients with hidradenitis suppurativa: 12-week interim analysis of post-marketing surveillance in Japan.The Journal of dermatology · 2022Observational
- Overall Impairment of Quality of Life in Japanese Patients with Hidradenitis Suppurativa: Comparison with National Standard.Acta dermato-venereologica · 2022Article
- Recent advances in hidradenitis suppurativa: Role of race, genetics, and immunology.Frontiers in genetics · 2022Article
- Characterization of comorbidity heterogeneity among 13,667 patients with hidradenitis suppurativa.JCI insight · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
Hidradenitis suppurativa (HS) is a chronic relapsing skin disease localized mainly on the apocrine gland-bearing areas. In Japan, HS is yet to be fully understood, and no criteria have been established for its diagnosis or severity assessment. The purpose of this study was to investigate and characterize HS in Japan. We conducted a nationwide questionnaire-based study, in which Japanese diagnostic criteria were proposed. Question items included age, sex, disease duration, past history, family history, smoking status, disease severity scores (Hurley stage, modified Sartorius score and Physician Global Assessment [PGA] score), treatments, comorbidities and prognosis. We analyzed 300 patients (219 males and 81 females) diagnosed with HS based on our criteria. Average disease duration was 92.3 ± 6.82 months. Only 12 (4%) patients had a family history of HS. Disease severity was classified by PGA score (mild, 100 [33.3%]; moderate, 133 [44.3%]; severe, 34 [11.3%]; most severe, 29 [9.7%]) and Hurley stage (I, 69 [23%]; II, 109 [36.3%]; III, 121 [40.3%]). Disease severities based on PGA score and Hurley stage were positively correlated to modified Sartorius score using the Kruskal-Wallis test (P < 0.001, respectively). Patients with diabetes mellitus showed higher PGA scores (χ
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.